Related Experiment Video

Updated: Sep 22, 2026

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors
09:04

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors

Published on: March 15, 2016

Ras regulation of vascular endothelial growth factor and angiogenesis

J Rak1, R S Kerbel

  • 1Department of Medical Biophysics, Division of Cancer Biology Research, Sunnybrook Health Science Centre, University of Toronto, Toronto, Ontario M6G 2M9, Canada.

Methods in Enzymology
|June 13, 2001
PubMed

Insights

Targeting Ras proteins in cancer may hinder tumor growth by reducing angiogenesis and increasing cancer cell sensitivity to apoptosis. This approach could synergize with other anti-cancer therapies for enhanced efficacy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Ras proteins play a critical role in tumor angiogenesis, the process of new blood vessel formation that supports tumor growth.
  • Understanding the multifaceted role of Ras is crucial for developing effective cancer therapies.

Purpose of the Study:

  • To explore the consequences of pharmacologically targeting Ras proteins in the context of tumor angiogenesis.
  • To investigate the potential of Ras antagonists and signal transduction inhibitors in cancer treatment.

Main Methods:

  • Utilizing various pharmacological compounds and antibodies to target Ras proteins.
  • Exploring the effects on tumor cell angiogenic competence, vascular dependence, and endothelial cell responses.

Main Results:

  • Pharmacologic targeting of Ras may lead to partial obliteration of tumor cell angiogenic competence.
  • It can increase tumor vascular dependence and sensitization to apoptosis.
  • Direct inhibition of endothelial cell responses to proangiogenic stimuli is also a potential outcome.

Conclusions:

  • Targeting Ras proteins offers a promising strategy for cancer therapy by disrupting tumor angiogenesis.
  • Ras antagonists and signal transduction inhibitors may synergize with other anti-angiogenic modalities, such as endostatin or low-dose chemotherapy, for enhanced anti-cancer effects.

More Related Videos

In Vitro Model of Coronary Angiogenesis08:03

In Vitro Model of Coronary Angiogenesis

Published on: March 10, 2020

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies09:03

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies

Published on: June 30, 2023

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Autoregulation of Blood Flow01:17

Autoregulation of Blood Flow

Autoregulation mechanisms are characterized by their inherent capacity for self-regulation without necessitating specific nervous stimulation or endocrine control. These mechanisms facilitate the adjustment of blood flow and, therefore, perfusion specific to each tissue region. This self-regulation encompasses chemical signals and myogenic controls.
Chemical Signaling in Autoregulation
Chemical signaling operates at the precapillary sphincter level, inciting either contraction or relaxation.